Mason Shih

Mason Shih currently serves as Senior Vice President and Head of Drug Safety at Revolution Medicines, where responsibilities include developing the drug safety organization and pharmacovigilance system. Previously, Mason held the position of Vice President of Safety Science at BioMarin Pharmaceutical Inc., focusing on safety for rare disease drug development. At Roche, Mason was Global Head of Safety Risk Management, overseeing pharmacovigilance activities across the company’s portfolio. Prior roles include Site Head of Safety Risk Management in Asia Pacific, Site Head of SSF Drug Safety and Group Head for Oncology at Genentech, and various positions at Perlegen Sciences, Women First Health Care, and in academia. Mason holds an MD from the University of Virginia, an MBA from UCLA Anderson School of Management, and a BA in Biology from the University of Virginia.